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The gut hormone ghrelin is known to activate hypothalamic AMPK, a crucial metabolic sensor controlling
energy balance. In this issue of Cell Metabolism, Anderson et al. (2008) show that CaMKK2 mediates this
effect by forming a unique complex of AMPKa/b with acetyl-CoA carboxylase (ACC) in a pathway distinct
from the more established AMP/LKB1 pathway.Over the last decade, attention has been
focused on elucidating the role of the cen-
tral nervous system (CNS) in the regula-
tion of appetite, energy expenditure, and
metabolism. Combined genetic and phar-
macological manipulations have clearly
defined a number of critical neural popu-
lations, signaling steps, and pathways,
and the associated cellular events are
now being elucidated. A central player is
the adipose-specific protein leptin, which
is secreted in conditions of nutrient ex-
cess and is thought to act at least in part
on the neurons within the arcuate nucleus
(ARC) and the ventromedial hypothala-
mus to modulate the expression of neuro-
peptides such as neuropeptide Y (NPY),
agouti-related peptide (AgRP), and a-
melanocyte-stimulating hormone (aMSH)
to regulate food intake and metabolic
events. More recently, the orexigenic (food
intake-promoting) gut-derived peptide
ghrelin has been shown to impact many of
the same pathways. The opposing actions
of leptin and ghrelin converge within the
basal hypothalamus on the AMP-activated
protein kinase (AMPK) system, a highly
conserved sensor of cellular energy status
present in all eukaryotic cells.
AMPK exists as a heterotrimeric com-
plex of the catalytic a subunit and regula-
tory b and g subunits that responds to
a change in the AMP/ATP ratio. The sub-sequent rise in AMP results in the alloste-
ric activation of AMPK, but it is also known
to facilitate the phosphorylation of AMPK
by the upstream kinase LKB1. In vitro
studies of cells lacking LKB1 also have
shown a basal phosphorylation and
activity of AMPK, indicating the presence
of an additional upstream kinase. This
was identified as the Ca2+/calmodulin
(CaM)-dependent protein kinase kinase
(CaMKK; Hawley et al., 2005). In this is-
sue, Anderson et al. (2008) demonstrate
an in vivo role for CaMKK2 in regulating
hypothalamic AMPK activity.
Some of the first evidence for physio-
logical activation of the AMPK system
came from studies that reported leptin-
dependent activation of the a2 isoform
of AMPK in skeletal muscle (Minokoshi
et al., 2002). More importantly for this dis-
cussion, hormones (e.g., leptin and insu-
lin) and nutrients (e.g., glucose) have
been demonstrated to inhibit AMPKa2
activity in the hypothalamus, an effect
that correlates with the behavioral actions
of central leptin, insulin, and glucose to
inhibit food intake (Kahn et al., 2005).
Many separate biochemical studies have
now elucidated some specific substrates
for AMPK (Towler and Hardie, 2007) that
contributed to placing the AMPK pathway
in a more physiological context (Pocai
et al., 2006). Leptin, through activation ofCell Metabcentral receptors within the ARC, leads
to reducedactivationofAMPK, aconcom-
itant increase in activity of acetyl-CoA
carboxylase (ACC), and increased for-
mation of malonyl-CoA. As malonyl-CoA
is a key regulator of the mitochondrial
enzyme carnitine palmitoyltransferase
(CPT-1), this ultimately results in an in-
crease in metabolic flux in the fatty acid
synthesis pathway and decreased b-oxi-
dation. Despite these advances, the exact
mechanisms by which leptin decreases
the activity of AMPK remain unknown,
with their elucidation perhaps compli-
cated by the multiplicity of signaling
events emanating from activation of the
leptin receptor (including PI3K, STAT2,
MAPK, and Ca2+; see Figure 1A).
CaMKK2 is expressed predominantly in
the CNS. The growth hormone secreta-
gogue receptor (GHS-R) is known to be
coupled toGq (thereby activating intracel-
lular Ca2+). Means and colleagues (Ander-
son et al., 2008) therefore postulated that
the recently described actions of ghrelin
to activate hypothalamic AMPK (Ander-
sson et al., 2004) might be mediated
through CaMKK2. They tested this hy-
pothesis by generating and extensively
phenotyping CaMKK2 null mice.
Their detailed analysis of CaMKK2
expression in ARC punches of normal
mice revealed an up to 20-fold enrichmentolism 7, May 2008 ª2008 Elsevier Inc. 361
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PreviewsFigure 1. AMPK Regulates Energy Balance in the Brain
(A) Postulated mechanisms by which leptin, insulin, and other pathways regulate food intake by decreasing the hypothalamic activity of AMPK.
(B) Activation of the Gq-linked G protein-coupled receptors, such as by ghrelin, results in activation of the CaMKK2, AMPKa/b, and ACC complex.within thehypothalamus,whichcorrelated
with the enrichment of the neuropeptides
AgRP/NPY and pro-opiomelanocortin
(POMC). Interestingly, mice lacking
CaMKK2 displayed a dramatic and spe-
cific reduction in orexigenic neuropeptide
expression (NPY/AgRP, but not POMC),
reduced AMPK activation, and resistance
to exogenous ghrelin-induced feeding.
The efficacy of 2-deoxyglucose,which ac-
tivates AMPK via AMP/LKB1, in stimulat-
ing food intake in CaMKK2 null mice high-
lights that the AMPK pathway remained
intact. Consistent with the observed
changes in neuropeptide levels, CaMKK2
null mice exhibited reduced fasting-in-
duced hyperphagia (as seen in NPY/AgRP-
deficient mice). CaMKK2 null mice also
weighed less and stored less fat when
maintainedonchoworhigh-fatdiet.Notun-
expectedly, therefore, these mice showed
a resistance to the metabolic alterations
that accompanyahigh-fatdiet, suchasglu-
cose intolerance and insulin resistance.
The known effect of AMPK on carbohy-
drate and lipid metabolism suggests that
this is a key factor in the development
and possible treatment of metabolic dis-
orders. A challenge for drug design and
delivery will still be the selective inhibition
of CaMKK2 in relevant tissue sites. While
Anderson et al. (2008) do show that a gen-
eral CaMKK inhibitor, STO-609, is effec-362 Cell Metabolism 7, May 2008 ª2008 Elstive in reducing food intake in wild-type
and not in CaMKK2-deficient mice,
CaMKK2 is also expressed in other CNS
area such as the hippocampus, neocor-
tex, andcerebellum. There are also a num-
ber of additional substrates, such as
CaMKI and CaMKIV. At least in mice, hip-
pocampal CaMKK2 is thought to be im-
portant in activation of CREB-dependent
transcription, and CaMKK2 null mice and
transgenic mice carrying dominant-nega-
tive CaMKIV alleles exhibit impairments in
long-term memory (Peters et al., 2003;
Kang et al., 2001). The activation of
AMPK by CaMKK2 in additional tissues
such as endothelial cells and lymphocytes
is also likely to be important in any side ef-
fects produced by targeting this pathway.
Despite these issues, a key finding of
Anderson et al. (2008) is the demonstra-
tion of a unique complex comprising
CaMKK2, AMPKa/b, Ca2+/CaM, and
ACC (see Figure 1B). The ability of spe-
cific CaMKK isoforms to substitute for
the AMPKg subunit provides an alternate
means of stabilizing AMPK and conferring
Ca2+ sensitivity and AMPK indepen-
dence. Given the number of AMPK sub-
units and downstream targets including
metabolically relevant molecules such as
HMG-CoA reductase, TSC2, and IRS1
(Towler and Hardie, 2007), the next chal-
lenge will be to understand how each ofevier Inc.these complexes is activated and/or as-
sembled through this pathway and to dis-
cern any further tissue-specific effects.
These findings further cement the regula-
tion of malonyl-CoA, and subsequently
CPT-1 activity, as a central point in the
regulation of energy expenditure and sub-
sequently ingestive behavior.
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